BidaskClub Upgrades Ra Pharmaceuticals (NASDAQ:RARX) to “Sell”

Share on StockTwits

Ra Pharmaceuticals (NASDAQ:RARX) was upgraded by equities research analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a report issued on Wednesday, BidAskClub reports.

RARX has been the subject of a number of other reports. SunTrust Banks downgraded shares of Ra Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, October 14th. Leerink Swann downgraded shares of Ra Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $48.00 price target on the stock. in a research note on Friday, October 11th. BMO Capital Markets lowered shares of Ra Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $48.00 price target on the stock. in a report on Thursday, October 10th. Robert W. Baird lowered shares of Ra Pharmaceuticals from an “outperform” rating to a “neutral” rating and set a $48.00 price target on the stock. in a report on Thursday, October 10th. Finally, Royal Bank of Canada reissued a “sector perform” rating and set a $48.00 price objective on shares of Ra Pharmaceuticals in a research note on Friday, October 11th. One analyst has rated the stock with a sell rating and thirteen have assigned a hold rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $45.36.

Shares of NASDAQ:RARX opened at $46.99 on Wednesday. The company has a current ratio of 25.73, a quick ratio of 25.73 and a debt-to-equity ratio of 0.01. The firm has a market cap of $2.22 billion, a price-to-earnings ratio of -22.81 and a beta of 1.50. The stock’s 50-day moving average price is $46.70 and its two-hundred day moving average price is $32.58. Ra Pharmaceuticals has a 12-month low of $14.50 and a 12-month high of $47.35.

Ra Pharmaceuticals (NASDAQ:RARX) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.55) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.50) by ($0.05). The firm had revenue of $3.00 million for the quarter. As a group, research analysts forecast that Ra Pharmaceuticals will post -2.05 earnings per share for the current fiscal year.

In other Ra Pharmaceuticals news, insider Alonso Ricardo sold 2,285 shares of the business’s stock in a transaction that occurred on Thursday, October 17th. The shares were sold at an average price of $46.70, for a total transaction of $106,709.50. Following the completion of the sale, the insider now directly owns 6,858 shares in the company, valued at $320,268.60. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Ramin Farzaneh-Far sold 10,595 shares of the stock in a transaction on Friday, November 15th. The stock was sold at an average price of $46.66, for a total transaction of $494,362.70. Following the completion of the sale, the insider now directly owns 8,521 shares of the company’s stock, valued at approximately $397,589.86. The disclosure for this sale can be found here. In the last three months, insiders have sold 44,070 shares of company stock valued at $1,619,601. Corporate insiders own 4.30% of the company’s stock.

Several large investors have recently bought and sold shares of the stock. Marshall Wace LLP purchased a new stake in Ra Pharmaceuticals during the 1st quarter worth $229,000. FMR LLC boosted its position in shares of Ra Pharmaceuticals by 12.9% in the first quarter. FMR LLC now owns 466,834 shares of the company’s stock worth $10,457,000 after buying an additional 53,445 shares during the period. Virginia Retirement Systems ET AL grew its stake in shares of Ra Pharmaceuticals by 12.9% in the second quarter. Virginia Retirement Systems ET AL now owns 10,500 shares of the company’s stock valued at $316,000 after buying an additional 1,200 shares in the last quarter. Moody Aldrich Partners LLC grew its stake in shares of Ra Pharmaceuticals by 2.8% in the second quarter. Moody Aldrich Partners LLC now owns 41,039 shares of the company’s stock valued at $1,234,000 after buying an additional 1,134 shares in the last quarter. Finally, Candriam Luxembourg S.C.A. raised its holdings in shares of Ra Pharmaceuticals by 15.0% during the 2nd quarter. Candriam Luxembourg S.C.A. now owns 1,178,000 shares of the company’s stock valued at $35,267,000 after buying an additional 154,000 shares during the period.

About Ra Pharmaceuticals

Ra Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules.

See Also: What is the role of the G-20?

Analyst Recommendations for Ra Pharmaceuticals (NASDAQ:RARX)

Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.